Medpace slides 20.8% as Q1 book-to-bill drops below 1 and president retirement is disclosed

Medpace Holdings, Inc. (MEDP) is down 20.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied to investor concern about forward demand after Medpace reported a net book-to-bill ratio below 1.0 in Q1 2026, signaling bookings lagged recognized revenue. A leadership update (the company’s president planning to retire) may have added uncertainty, even as revenue and earnings rose year over year.

Details:

Medpace reported Q1 2026 revenue of $706.6 million, up 26.5% year over year, and GAAP diluted EPS of $4.28.

Net new business awards were $618.4 million, producing a net book-to-bill ratio of 0.88x; backlog was $2,929.2 million at quarter-end.

The company maintained its 2026 outlook ranges for revenue ($2.755–$2.855 billion) and GAAP EPS ($16.68–$17.50).

An 8-K disclosed that President Jesse Geiger plans to retire effective May 31, 2026, with CEO August Troendle set to reassume the president role until a successor is appointed.

Sources:

SEC, Associated Press, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MEDP Insider Trading Activity

$MEDP insiders have traded $MEDP stock on the open market 26 times in the past 6 months. Of those trades, 0 have been purchases and 26 have been sales.

Here’s a breakdown of recent trading of $MEDP stock by insiders over the last 6 months:

AUGUST J. TROENDLE (CEO) has made 0 purchases and 15 sales selling 278,418 shares for an estimated $167,599,756.
JESSE J GEIGER (President) has made 0 purchases and 4 sales selling 76,238 shares for an estimated $41,107,589.
SUSAN E BURWIG (Exec. VP, Operations) has made 0 purchases and 3 sales selling 40,000 shares for an estimated $24,283,020.
STEPHEN P EWALD (General Counsel & Corp. Secy.) sold 15,230 shares for an estimated $9,120,485
ROBERT O. KRAFT sold 6,472 shares for an estimated $3,830,453
FRED B JR DAVENPORT sold 5,972 shares for an estimated $3,474,987
KEVIN M. BRADY (CFO & Treasurer) sold 3,000 shares for an estimated $1,771,050

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EARLY ACCESS

Receive MEDP Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$MEDP Hedge Fund Activity

We have seen 363 institutional investors add shares of $MEDP stock to their portfolio, and 354 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

AQR CAPITAL MANAGEMENT LLC added 324,293 shares (+31.6%) to their portfolio in Q4 2025, for an estimated $182,139,163
MAWER INVESTMENT MANAGEMENT LTD. removed 239,472 shares (-37.0%) from their portfolio in Q4 2025, for an estimated $134,499,448
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 200,597 shares (-63.1%) from their portfolio in Q4 2025, for an estimated $112,665,305
FMR LLC added 195,907 shares (+2507.1%) to their portfolio in Q4 2025, for an estimated $110,031,166
FRANKLIN RESOURCES INC added 183,645 shares (+158.6%) to their portfolio in Q4 2025, for an estimated $103,144,214
VULCAN VALUE PARTNERS, LLC removed 152,866 shares (-76.4%) from their portfolio in Q4 2025, for an estimated $85,857,188
FINDLAY PARK PARTNERS LLP removed 127,900 shares (-42.3%) from their portfolio in Q4 2025, for an estimated $71,835,035

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$MEDP Congressional Stock Trading

Members of Congress have traded $MEDP stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $MEDP stock by members of Congress over the last 6 months:

REPRESENTATIVE DAVID TAYLOR has traded it 3 times. They made 2 purchases worth up to $30,000 on 02/26, 01/29 and 1 sale worth up to $15,000 on 01/16.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $50,000 on 01/15.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$MEDP Analyst Ratings

Wall Street analysts have issued reports on $MEDP in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Jefferies issued a "Buy" rating on 02/13/2026

To track analyst ratings and price targets for $MEDP, check out Quiver Quantitative's $MEDP forecast page.

$MEDP Price Targets

Multiple analysts have issued price targets for $MEDP recently. We have seen 7 analysts offer price targets for $MEDP in the last 6 months, with a median target of $522.0.

Here are some recent targets:

Luke Sergott from Barclays set a target price of $500.0 on 03/06/2026
Ryan Halsted from RBC Capital set a target price of $522.0 on 03/03/2026
Charles Rhyee from TD Cowen set a target price of $419.0 on 02/18/2026
David Windley from Jefferies set a target price of $560.0 on 02/13/2026
Michael Cherny from Leerink Partners set a target price of $485.0 on 02/11/2026
Jailendra Singh from Truist Securities set a target price of $539.0 on 02/11/2026
Sean Dodge from BMO Capital set a target price of $600.0 on 11/13/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.